Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a healthcare enterprise focused on affordability and AI-driven therapies, announced on May 21, 2026, that it entered into a non-binding Letter of Intent to evaluate a potential acquisition of a Management Services Organization (MSO). If completed, the transaction would strengthen Tevogen’s healthcare infrastructure and support its transition into a revenue-generating enterprise, combining its biotechnology arm (Tevogen Bio) and technology arm (Tevogen.AI) with a new healthcare services division. The proposed deal could contribute to Tevogen’s goal of achieving approximately $100 million in combined annual revenue, alongside other strategic initiatives like a previously announced contract research organization (CRO) evaluation. CEO Ryan Saadi, MD, MPH, stated that these potential acquisitions align with the company’s broader vision of expanding its healthcare capabilities. However, the transaction remains contingent on due diligence, definitive agreements, regulatory approvals, and customary closing conditions. Tevogen’s existing operations include Tevogen Bio, which completed a proof-of-concept trial for its genetically unmodified allogeneic T-cell therapy, targeting virology, oncology, and neurology. Its Tevogen.AI division leverages Microsoft and Databricks cloud services to accelerate drug development through predictive technologies, aiming to optimize clinical trials and reduce failure rates. The company also explores generics, biosimilars, medical devices, and insurance solutions to enhance patient access and healthcare efficiency. The acquisition is part of Tevogen’s broader strategy to integrate management services and contract research operations into its business model. While the company remains focused on life sciences and healthcare transactions, no guarantees exist that additional deals will materialize. Tevogen’s forward-looking statements highlight potential benefits from the transaction, including expanded revenue streams and advancements in its therapeutic pipelines for infectious diseases and cancer.